Literature DB >> 8156185

Pathophysiology of edema in congestive heart failure.

J P Navas1, M Martinez-Maldonado.   

Abstract

Congestive heart failure is one of the most important causes of peripheral edema seen in clinical practice. Edema in congestive heart failure is the result of the activation of a series of humoral and neurohumoral mechanisms that promote sodium and water reabsorption by the kidneys and expansion of the extracellular fluid. These mechanisms, in concert with abnormal Starling forces such as increased venous capillary pressure and decreased plasma oncotic pressure, promote fluid extravasation and edema formation. The management of edema in congestive heart failure is designed to improve cardiac function and to inhibit the hormonal and neurohumoral pathways that promote edema. The combination of diuretics and vasodilators or angiotensin converting enzyme inhibitors and, in some cases, cardiac inotropic agents is highly effective in achieving these goals and providing significant symptomatic improvement in patients with edema secondary to congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8156185

Source DB:  PubMed          Journal:  Heart Dis Stroke        ISSN: 1058-2819


  8 in total

1.  Urinary Proteolytic Activation of Renal Epithelial Na+ Channels in Chronic Heart Failure.

Authors:  Hong Zheng; Xuefei Liu; Neeru M Sharma; Yulong Li; Rainer U Pliquett; Kaushik P Patel
Journal:  Hypertension       Date:  2015-11-30       Impact factor: 10.190

2.  Increased renal ENaC subunits and sodium retention in rats with chronic heart failure.

Authors:  Hong Zheng; Xuefei Liu; U S Rao; Kaushik P Patel
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-15

Review 3.  Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys.

Authors:  Kaushik P Patel; Kenichi Katsurada; Hong Zheng
Journal:  Circ Res       Date:  2022-05-12       Impact factor: 23.213

4.  Renal denervation improves sodium excretion in rats with chronic heart failure: effects on expression of renal ENaC and AQP2.

Authors:  Hong Zheng; Xuefei Liu; Kenichi Katsurada; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

5.  An Injectable Microparticle Formulation Provides Long-Term Inhibition of Hypothalamic ERK1/2 Activity and Sympathetic Excitation in Rats with Heart Failure.

Authors:  Youssef W Naguib; Yang Yu; Shun-Guang Wei; Angie Morris; Brittany E Givens; Aml I Mekkawy; Robert M Weiss; Robert B Felder; Aliasger K Salem
Journal:  Mol Pharm       Date:  2020-08-04       Impact factor: 4.939

6.  Stent Placement for Malignant Inferior Vena Cava Syndrome in a Patient with Recurrent Colon Cancer.

Authors:  Shinichi Morita; Shunsuke Sugawara; Takeshi Suda; Didik Prasetyo; Yuka Kobayashi; Takahiro Hoshi; Satoshi Abe; Kazuyoshi Yagi; Shuji Terai
Journal:  Intern Med       Date:  2020-07-28       Impact factor: 1.271

7.  Plasma Volume and Renal Function Predict Six-Month Survival after Hospitalization for Acute Decompensated Heart Failure.

Authors:  Kenneth C Bilchick; Nathaniel Chishinga; Alex M Parker; David X Zhuo; Mitchell H Rosner; LaVone A Smith; Hunter Mwansa; Jacob N Blackwell; Peter A McCullough; Sula Mazimba
Journal:  Cardiorenal Med       Date:  2017-11-03       Impact factor: 2.041

8.  An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics.

Authors:  Youssef W Naguib; Brittany E Givens; Giang Ho; Yang Yu; Shun-Guang Wei; Robert M Weiss; Robert B Felder; Aliasger K Salem
Journal:  Drug Deliv Transl Res       Date:  2021-02       Impact factor: 4.617

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.